Percentage of all patient months for adult patients (>= 18 years old) whose delivered peritoneal dialysis dose was a weekly Kt/V urea >= 1.7 (dialytic + residual).
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
The purpose of this meeting is for Advisory Group members to raise questions and share perspectives verbally regarding the measures under endorsement review for their respective E&M committee. No voting occurs during these virtual meetings. Rather, Advisory Group members will be asked to review the measures assigned to their respective committee and come to the meeting to ask questions and provide feedback regarding the strengths and limitations of the measures.
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
The Fall 2024 E&M Cycle is underway, and there are several ways to get involved and provide thoughts about measures under review! The Partnership for Quality Measurement (PQM) will be hosting a Public Comment Listening Session on November 21 so interested parties can provide verbal comments about the Fall 2024 measures. On November 15, the Fall 2024 measures will be posted for public comment, at which point any interested party may submit a comment through the PQM website or register to provide a comment verbally during the November 21 Public Comment Listening Session.
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
The purpose of this meeting is for Recommendation Group members to discuss and share perspectives regarding the measures under endorsement review for their respective E&M committee. Endorsement voting occurs during these virtual meetings. Advisory Group members are invited to attend these Recommendation Group meetings to listen to the discussion. Measure developers/stewards are invited and encouraged to attend, as they will have the opportunity to respond to the Recommendation Group discussion during the meeting.
This intermediate outcome eCQM captures the proportion of visits for patients of all ages that experience emergency care access barriers during a one-year performance period.
The Excess Antibiotic Duration for Adult Hospitalized Patients with Uncomplicated Community-Acquired Pneumonia measure is a process measure representing the annual percentage of hospitalized adults with uncomplicated community-acquired pneumonia who receive an excess antibiotic duration. The measure will be calculated using electronic health record (EHR) data and is intended for use at the facility level for both quality improvement and pay-for-performance.